Type 2 Diabetes Treatment: Focus Shifts to Heart & Kidney Protection | NICE vs ADA Guidelines
A significant shift is underway in how type 2 diabetes is treated. An update to the National Institute for Health and Care Excellence (NICE) guideline NG28, the body responsible for guiding clinical policies in the United Kingdom, is refocusing therapeutic priorities: controlling glucose remains essential, but protecting the heart and kidneys from the outset of treatment is now an explicit priority. This change isn’t happening in isolation, however, and sparks debate as it aligns with and diverges from recommendations from the American Diabetes Association (ADA), a leading reference point in the United States.
From Glycemic Control to Protecting Target Organs
For decades, the primary goal in type 2 diabetes management was reducing glycated hemoglobin (HbA1c). The logic was straightforward: less glucose, fewer complications. However, cardiovascular outcome studies have reshaped this view. We now know that a substantial proportion of deaths in people with diabetes stem from cardiovascular disease and heart failure, not just hyperglycemia alone. As CNN Brasil reported, diabetes is a growing concern, and cardiovascular complications are a major contributor to mortality.
The new NICE guideline incorporates this evidence by recommending earlier use of medications with proven cardiovascular and renal benefits, particularly SGLT2 inhibitors, in patients at increased risk. This represents a move towards a more holistic approach, recognizing the interconnectedness of diabetes with other organ systems.
NICE vs. ADA: Convergences and Differences
Early Cardiovascular Protection
Both NICE and the ADA recognize the benefits of medication classes like:
- SGLT2 inhibitors
- GLP-1 receptor agonists
Both organizations recommend prioritizing these medications in patients with:
- Established cardiovascular disease
- Heart failure
- Chronic kidney disease
The key difference lies in the operational emphasis. The ADA, in its Standards of Care, adopts a highly individualized approach, allowing for broad flexibility in therapeutic choices, even considering obesity as a central factor when prioritizing GLP-1 agonists.
NICE, as an organization with a strong focus on cost-effectiveness within a public healthcare system (the NHS), structures recommendations more closely tied to formal risk criteria and population-level economic impact. In other words:
- ADA → clinical focus, individual with broad therapeutic freedom.
- NICE → clinical focus + health system rationality.
Is Metformin Still First Line?
The ADA continues to position metformin as the traditional initial therapy in most cases, barring contraindications or a high risk of cardiovascular complications, where SGLT2 or GLP-1 inhibitors may be initiated earlier.
NICE goes further, expanding the possibility of initiating SGLT2 inhibitors sooner in certain profiles, particularly when cardiovascular or renal risk is significant. This nuance is critical: the British guideline makes the shift away from the exclusive centrality of metformin more explicit.
Glycemic Monitoring
The ADA has been expanding recommendations for continuous glucose monitoring (CGM), even in patients not using insulin in certain contexts. According to the NICE guideline, intermittent CGM (isCGM) is recommended in insulin-treated patients with recurrent or severe hypoglycemia, impaired hypoglycemia awareness, disability preventing self-monitoring of blood glucose, or a need for more than eight daily determinations.
NICE adopts a more restrictive stance, generally based on cost-effectiveness within the British public system.
Body Weight as a Central Axis
The ADA strongly emphasizes obesity as a priority therapeutic target, advocating for aggressive weight loss goals and the use of specific therapies for weight reduction. NICE recognizes the importance of weight but maintains a therapeutic structure more centered on cardiovascular and renal risk.
What Does This Mean for Brazil?
In Brazil, where over 10% of the adult population lives with diabetes and nearly half of patients may have associated cardiovascular disease, this discussion is far from academic. The country faces a hybrid scenario:
- A public system with budgetary limitations
- A private sector with increasing access to innovative therapies
- A high prevalence of obesity and cardiometabolic risk
The NICE guideline can serve as a model for technology incorporation decisions within the SUS (Brazil’s public health system), while the ADA recommendations align more directly with individualized clinical practice in the private sector.
A Broader Shift Than It Appears
We are witnessing something larger than a simple protocol update. Type 2 diabetes is moving away from being treated solely as a glycemic disorder and is increasingly recognized as a systemic cardiometabolic syndrome. The goal is no longer just to lower numbers, but to reduce mortality and preserve vital organs. The convergence between NICE and ADA reinforces that this isn’t a local trend, but a global movement based on robust evidence. The divergence, in turn, reveals that science and health policy walk hand in hand, and clinical decisions are similarly economic and structural decisions.
The updated NICE guidance, published February 2026, consolidates a person-centered care model, incorporates recommendations on continuous glucose monitoring (MCG), and redefines the initial therapeutic standard with modified-release metformin plus a sodium-glucose cotransporter 2 (iSGLT2) inhibitor for most patients, regardless of established cardiovascular or renal comorbidities. Cardioteca provides further details on these changes.
Text written by endocrinologist Filippo Pedrinola (CRM/SP 62253 | RQE 26961), National Head of Endocrinology at Brazil Health